2-(3,4-dichlorophenyl)-1-(4-(6-methylpyridin-2-yl)piperazin-1-yl)ethanone

ID: ALA5287346

Max Phase: Preclinical

Molecular Formula: C18H19Cl2N3O

Molecular Weight: 364.28

Names and Identifiers

Canonical SMILES:  Cc1cccc(N2CCN(C(=O)Cc3ccc(Cl)c(Cl)c3)CC2)n1

Standard InChI:  InChI=1S/C18H19Cl2N3O/c1-13-3-2-4-17(21-13)22-7-9-23(10-8-22)18(24)12-14-5-6-15(19)16(20)11-14/h2-6,11H,7-10,12H2,1H3

Standard InChI Key:  ZCOJIWYCKJBLPE-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   -0.7034   -0.8248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4233   -0.4218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1322   -0.8437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8521   -0.4407    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5610   -0.8626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2809   -0.4596    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -3.5501   -1.6875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2591   -2.1094    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -2.8302   -2.0905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1214   -1.6686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0054   -0.4029    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0054    0.4219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7034    0.8438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4233    0.4407    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1322    0.8626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1214    1.6875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8302    2.1094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5501    1.7064    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5610    0.8815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2809    0.4784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8520    0.4596    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4342   -0.3841    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7252   -0.8060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6925   -1.6496    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  5  7  1  0
  7  8  1  0
  7  9  2  0
  3 10  2  0
  9 10  1  0
  1 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 15 21  2  0
 19 21  1  0
 14 22  1  0
 11 23  1  0
 22 23  1  0
  1 24  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA5287346

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 364.28

Molecular Weight (Monoisotopic): 363.0905

AlogP: 3.59

#Rotatable Bonds: 3

Polar Surface Area: 36.44

Molecular Species: NEUTRAL

HBA: 3

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 4

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 7.19

CX LogP: 3.71

CX LogD: 3.50

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.84

Np Likeness Score: -1.94

References

1. Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ..  (2023)  Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.,  86  [PMID:37148788] [10.1016/j.bmc.2023.117295]

Source

Source(1):

• Scientific Literature